LUCD.US Lucid Diagnostics Inc

Healthcare Health Care Equipment & Supplies USA Stocks
0.4491 USD
Close of Nov 15, 2026
0.3030 1.63
Market cap
USD 87.4M
P/E
-
P/B
14.85x
ROE
-725.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is LUCD.US undervalued?

Graham number

The Graham number of Lucid Diagnostics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Lucid Diagnostics Inc fundamental analysis

No fundamental analysis for Lucid Diagnostics Inc yet.

Lucid Diagnostics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Lucid Diagnostics Inc

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of pr…

Full company profile